Kallam Anji Reddy Quotes

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

There's always going to be the need for new medications, better medications.

I keep encouraging the pharmaceutical companies to put more money into R&D.

Drug discovery is terribly expensive, just to find out how one drug could or could not work and all its side effects.

I want to make a drug. I want the science to be more than imaginary, where I think, 'We're learning these fundamental principles, blah, blah, blah, blah, blah.' I think we are doing that, but I want to do something really practical. I want to actually, in my lifetime, help people.

I really was inspired by the possibility of more directly being involved in the development of drugs myself.

The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.

On the third stage is used for medicine, it is not known to the public.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

Pharmacology is benefited by the prepared mind. You need to know what you are looking for.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

All I ever promised was that I was sure I could develop a new pharmacological agent which might answer a physiological question. Any utility would be implicit in that answer.

When you work in the pharmaceutical industry you realize that there's a lot out of people's control, and there's ways that people can be helped.

There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.

I had seen a Pfizer's pilot plant in 1965 and decided that, 'I'll build a Pfizer.' If not Pfizer, I have built Dr Reddy's, which is no less respectable.

My choice of learning pharmacy was driven by my interests, curiosity, and a desire to seek new medicines for patients.

I agree, the world would be a better place if doctors were less enthusiastic about adopting very new drugs.

Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

Analytical pharmacology has got an important and exciting future.

If you sit in a position where decisions that you take would have a serious effect on people, you can't ignore a lot of experience around the world which says this drug has these negative effects.

And there are lots of drug companies that are working on cure or medicine.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

If we can actually decrease the failure rate from nine out of 10 drugs failing in clinical trials and instead have seven out of 10 instead failing, that is a major victory for drug discovery and for people having better therapy.